This technology is a gene panel that uses next generation sequencing to predict progression of esophagitis and Barrett’s esophagus to dysplasia and/or esophageal adenocarcinoma.
Current guidelines for prevention and early detection of esophageal adenocarcinoma recommend repeat surveillance endoscopies with multiple biopsies followed by pathological examination to detect metaplasia and dysplasia. The detection and diagnosis of dysplasia is hampered by sampling errors and high interobserver diagnostic variability. Surveillance could be improved by implementation of risk stratification.
This gene panel uses targeted next generation sequencing and a unique combination of sequencing primers. The assay can be performed with DNA from fresh or paraffin-embedded formalin fixed (FFPE) samples. DNA may be obtained from Barrett’s tissue samples or cytology preparations, as well as circulating cells and DNA from blood. Data analysis includes reporting single nucleotide variants, indels, genomic losses and gains, copy number variations, and copy-neutral loss of heterozygosity. This technology can be used to stratify patients with Barrett’s esophagus into sub-groups with low or high-risk of progressing to dysplasia and adenocarcinoma.
Antonia Sepulveda, M.D., Ph.D.
Patent Pending (US 20200071767)
IR CU18204
Licensing Contact: Joan Martinez